SEC Company Response from NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Nov 15, 2017
NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Nov. 15, 2017 · CIK: 0000906709 · Accession: 0001193125-17-344203
AI Filing Summary & Sentiment
File numbers found in text: 000-24006
Letter
VIA EDGAR Office of Healthcare and Insurance United States Securities and Exchange Commission Division of Corporation Finance Attention: Ibolya Ignat, Senior Staff Accountant Re: Nektar Therapeutics Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 1, 2017 File No. 000-24006
Dear Ms. Ignat:
We are in receipt of the letter from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) dated November 1, 2017, regarding the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation (the “Company”), on March 1, 2017. We hereby respectfully request that the Commission grant an extension of the deadline for the Company to provide its response to the Staff’s comment in the letter to November 24, 2017.
If you have any questions regarding this request, please do not hesitate to contact the undersigned at (415) 482-5570.
Sincerely,
/s/ Gil M. Labrucherie
Show Raw Text
CORRESP 1 filename1.htm CORRESP Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, California 94158-2117 November 15, 2017 VIA EDGAR Office of Healthcare and Insurance United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ibolya Ignat, Senior Staff Accountant Re: Nektar Therapeutics Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 1, 2017 File No. 000-24006 Dear Ms. Ignat: We are in receipt of the letter from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) dated November 1, 2017, regarding the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation (the “Company”), on March 1, 2017. We hereby respectfully request that the Commission grant an extension of the deadline for the Company to provide its response to the Staff’s comment in the letter to November 24, 2017. If you have any questions regarding this request, please do not hesitate to contact the undersigned at (415) 482-5570. Sincerely, /s/ Gil M. Labrucherie Gil M. Labrucherie Senior Vice President and Chief Financial Officer cc: Angela Connell, Accounting Branch Chief, Division of Corporation Finance Jillian B. Thomsen, Senior Vice President, Finance and Chief Accounting Officer of Nektar Therapeutics Mark A. Wilson, Vice President and General Counsel of Nektar Therapeutics Sam Zucker, Esq., Sidley Austin LLP